Inclusive
7078
Renascience
4889
Chordia Therapeutics
190A
Kufu Company Holdings
4376
Cube
7112
JP Stock MarketDetailed Quotes
190A Chordia Therapeutics
- 391
- +80+25.72%
20min DelayMarket Closed Jan 9 15:30 JST
26.67BMarket Cap-12.57P/E (Static)
391High340Low11.38MVolume345Open311Pre Close4.27BTurnover93052wk High53.30%Turnover Ratio68.21MShares14252wk Low-31.11EPS TTM8.35BFloat Cap930Historical HighLossP/E (Static)21.35MShs Float142Historical Low-31.11EPS LYR16.40%Amplitude--Dividend TTM6.40P/B100Lot Size--Div YieldTTM
Chordia Therapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (FY)Aug 31, 2023 | (Q4)Aug 31, 2023 | (FY)Aug 31, 2022 | (FY)Aug 31, 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 2.5B | 0 | 0 | 800M |
| Cost of revenue | -24.89%1.5B | 515.34M | 2B | |||
| Gross profit | -398.07%-1.5B | -515.34M | 503.18M | |||
| Operating expense | 3.60%301.6M | 107.14%105.23M | -84.09%291.12M | -1.47B | 22.97%1.83B | 1.49B |
| Selling and administrative expenses | ---- | ---- | ---- | ---- | 9.66%188M | --171.44M |
| -Selling and marketing expense | ---- | ---- | ---- | ---- | 9.66%188M | --171.44M |
| Research and development costs | ---- | ---- | ---- | ---- | 25.18%1.66B | --1.32B |
| Total other operating income | ---- | ---- | ---- | ---- | 119.45%14.56M | --6.64M |
| Operating profit | -949.48%-1.8B | -18.51%-620.57M | 111.59%212.06M | -523.63M | -166.02%-1.83B | -687.76M |
| Net non-operating interest income (expenses) | -8.75M | 0 | ||||
| Total other finance cost | --8.75M | ---- | ---- | ---- | ---- | ---- |
| Net investment income | 70.59%-3.6M | 133.43%2.96M | -374.53%-12.24M | -8.85M | -729.58%-2.58M | -311K |
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||
| Income from associates and other participating interests | ||||||
| Special income (charges) | ||||||
| Other non-operating income (expenses) | -142.25%-10.96M | -374.93%-22.68M | -53.24%25.95M | 8.25M | -65.93%55.49M | 162.86M |
| Income before tax | -908.25%-1.82B | -23.81%-649.04M | 112.71%225.76M | -524.23M | -238.27%-1.78B | -525.21M |
| Income tax | 0.00%2.42M | 0.00%605K | 0.00%2.42M | 605K | 27.37%2.42M | 1.9M |
| Net income | -918.09%-1.83B | -23.78%-649.65M | 112.55%223.34M | -524.84M | -237.51%-1.78B | -527.11M |
| Net income continuous operations | -918.09%-1.83B | -23.78%-649.65M | 112.55%223.34M | ---524.84M | -237.51%-1.78B | ---527.11M |
| Noncontrolling interests | ||||||
| Net income attributable to the company | -918.09%-1.83B | -23.78%-649.65M | 112.55%223.34M | -524.84M | -237.51%-1.78B | -527.11M |
| Preferred stock dividends | ||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -918.09%-1.83B | -23.78%-649.65M | 112.55%223.34M | -524.84M | -237.51%-1.78B | -527.11M |
| Gross dividend payment | ||||||
| Basic earnings per share | -885.61%-31.11 | -10.22%-10.2489 | 112.56%3.96 | -9.2984 | -237.51%-31.5191 | -9.3386 |
| Diluted earnings per share | -885.61%-31.11 | -10.22%-10.2489 | 112.56%3.96 | -9.2984 | -237.51%-31.5191 | -9.3386 |
| Dividend per share | ||||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |